Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Blocking peptides and molecular mimicry as treatment for kidney disease.

Havasi A, Lu W, Cohen HT, Beck L, Wang Z, Igwebuike C, Borkan SC.

Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F1016-F1025. doi: 10.1152/ajprenal.00601.2015. Epub 2016 Sep 21. Review.

2.

SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.

Ozturk S, Papageorgis P, Wong CK, Lambert AW, Abdolmaleky HM, Thiagalingam A, Cohen HT, Thiagalingam S.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):638-43. doi: 10.1073/pnas.1514663113. Epub 2016 Jan 6.

3.

A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II.

Fu Y, Rope R, Fargue S, Cohen HT, Holmes RP, Cohen DM.

Clin Genet. 2015 Nov;88(5):494-8. doi: 10.1111/cge.12541. Epub 2014 Dec 26.

4.

Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.

Komers R, Xu B, Fu Y, McClelland A, Kantharidis P, Mittal A, Cohen HT, Cohen DM.

PLoS One. 2014 May 14;9(5):e96987. doi: 10.1371/journal.pone.0096987. eCollection 2014.

5.

Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.

Zeng L, Bai M, Mittal AK, El-Jouni W, Zhou J, Cohen DM, Zhou MI, Cohen HT.

Cancer Res. 2013 Sep 1;73(17):5371-80. doi: 10.1158/0008-5472.CAN-12-4707. Epub 2013 Jul 1.

6.

Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1.

Foy RL, Chitalia VC, Panchenko MV, Zeng L, Lopez D, Lee JW, Rana SV, Boletta A, Qian F, Tsiokas L, Piontek KB, Germino GG, Zhou MI, Cohen HT.

Hum Mol Genet. 2012 Dec 15;21(26):5456-71. doi: 10.1093/hmg/dds391. Epub 2012 Sep 21.

7.

Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL.

Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, Bharti A, Seldin DC, Lecker SH, Dominguez I, Cohen HT.

Nat Cell Biol. 2008 Oct;10(10):1208-16. doi: 10.1038/ncb1781. Epub 2008 Sep 21.

8.

Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex.

Foy RL, Song IY, Chitalia VC, Cohen HT, Saksouk N, Cayrou C, Vaziri C, Côté J, Panchenko MV.

J Biol Chem. 2008 Oct 24;283(43):28817-26. doi: 10.1074/jbc.M801407200. Epub 2008 Aug 6.

9.

Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.

Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S.

Cancer Res. 2008 Jul 15;68(14):5689-98. doi: 10.1158/0008-5472.CAN-07-6603.

10.

Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B.

Nolan VG, Ma Q, Cohen HT, Adewoye A, Rybicki AC, Baldwin C, Mahabir RN, Homan EP, Wyszynski DF, Fabry ME, Nagel RL, Farrer LA, Steinberg MH.

Am J Hematol. 2007 Mar;82(3):179-84.

11.

Renal-cell carcinoma.

Cohen HT, McGovern FJ.

N Engl J Med. 2005 Dec 8;353(23):2477-90. Review. No abstract available.

PMID:
16339096
12.

Jade-1, a candidate renal tumor suppressor that promotes apoptosis.

Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, Wang H, Cohen HT.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11035-40. Epub 2005 Jul 26.

13.

EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo.

Xu H, Tian W, Lindsley JN, Oyama TT, Capasso JM, Rivard CJ, Cohen HT, Bagnasco SM, Anderson S, Cohen DM.

Am J Physiol Renal Physiol. 2005 Apr;288(4):F855-66. Epub 2004 Nov 23.

14.

von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity.

Panchenko MV, Zhou MI, Cohen HT.

J Biol Chem. 2004 Dec 31;279(53):56032-41. Epub 2004 Oct 22.

15.
16.

Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data.

Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF.

BMC Cancer. 2003 Nov 27;3:31.

17.

The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1.

Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT.

J Biol Chem. 2002 Oct 18;277(42):39887-98. Epub 2002 Aug 6.

18.

Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer.

Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D.

J Biol Chem. 2000 Jul 7;275(27):20700-6.

19.

An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.

Cohen HT, Zhou M, Welsh AM, Zarghamee S, Scholz H, Mukhopadhyay D, Kishida T, Zbar B, Knebelmann B, Sukhatme VP.

Biochem Biophys Res Commun. 1999 Dec 9;266(1):43-50.

PMID:
10581162
20.

Advances in the molecular basis of renal neoplasia.

Cohen HT.

Curr Opin Nephrol Hypertens. 1999 May;8(3):325-31. Review.

PMID:
10456263
21.

Cellular activation triggered by the autosomal dominant polycystic kidney disease gene product PKD2.

Arnould T, Sellin L, Benzing T, Tsiokas L, Cohen HT, Kim E, Walz G.

Mol Cell Biol. 1999 May;19(5):3423-34.

23.

A far upstream cis-element is required for Wilms' tumor-1 (WT1) gene expression in renal cell culture.

Scholz H, Bossone SA, Cohen HT, Akella U, Strauss WM, Sukhatme VP.

J Biol Chem. 1997 Dec 26;272(52):32836-46.

24.

Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.

Knebelmann B, Ananth S, Cohen HT, Sukhatme VP.

Cancer Res. 1998 Jan 15;58(2):226-31.

25.

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP.

Mol Cell Biol. 1997 Sep;17(9):5629-39.

26.

Sp1 is a critical regulator of the Wilms' tumor-1 gene.

Cohen HT, Bossone SA, Zhu G, McDonald GA, Sukhatme VP.

J Biol Chem. 1997 Jan 31;272(5):2901-13.

27.

Different mechanisms of renal Na-K-ATPase regulation by protein kinases in proximal and distal nephron.

Satoh T, Cohen HT, Katz AI.

Am J Physiol. 1993 Sep;265(3 Pt 2):F399-405.

PMID:
8214099
28.
29.

Novel pathways of Na-K-ATPase regulation in kidney cells.

Katz AI, Satoh T, Takemoto F, Cohen HT.

Contrib Nephrol. 1993;101:7-11. Review. No abstract available.

PMID:
8385596
30.

Role of the phospholipase C-protein kinase C pathway in proximal tubule Na-K-ATPase regulation.

Satoh T, Ominato M, Cohen HT, Katz AI.

Trans Assoc Am Physicians. 1993;106:196-200. No abstract available.

PMID:
8036742
31.

Molecular biology in nephrology: an overview with emphasis on the study of renal cancer.

Cohen HT, Sukhatme VP.

Semin Nephrol. 1992 Nov;12(6):495-505. Review. No abstract available.

PMID:
1335610
32.

Renal adrenergic receptors: localization of [125I]prazosin binding sites along the microdissected rat nephron.

Cohen HT, Takemoto F, Satoh T, Katz AI.

Can J Physiol Pharmacol. 1992 Jul;70(7):1016-20.

PMID:
1451023
33.

Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron.

Takemoto F, Cohen HT, Satoh T, Katz AI.

Pflugers Arch. 1992 Jul;421(4):302-6.

PMID:
1357625
34.
35.

Regulation of renal Na-K-ATPase by eicosanoids: central role of the cytochrome P450-monooxygenase pathway.

Satoh T, Cohen HT, Katz AI.

Trans Assoc Am Physicians. 1992;105:86-92. No abstract available.

PMID:
1339239
36.

Localization of dopamine-1 receptors along the microdissected rat nephron.

Takemoto F, Satoh T, Cohen HT, Katz AI.

Pflugers Arch. 1991 Oct;419(3-4):243-8.

PMID:
1660593
37.
38.

Adrenergic receptors and catecholamine effects on sodium transport in the mammalian nephron.

Cohen HT, Katz AI.

Semin Nephrol. 1991 Mar;11(2):110-9. Review. No abstract available.

PMID:
1674621
39.

Red-cell surface charge in patients with nephrotic syndrome.

Cohen HT, Singh AK, Kasinath BS, Lewis EJ.

Lancet. 1988 Jun 25;1(8600):1459. No abstract available.

PMID:
2898609

Supplemental Content

Loading ...
Support Center